Table 3.
Prescribed statins reduce the mortality of PCa patients.
| Event/Total number | Crude HRa(95% confidence interval) | Adjusted HRb(95% confidence interval) | |
|---|---|---|---|
| Non-use of statins | 402/1826 | 1 (Reference) | 1 (Reference) |
| Use of statinc | |||
| Simvastatin | |||
| <180 DDD | 263/1101 | 1.11 (0.95–1.29) | 0.99 (0.85–1.16) |
| ≥180 DDD | 114/726 | 0.65 (0.53–0.80)∗∗∗ | 0.63 (0.51–0.77)∗∗∗ |
| Lovastatin | |||
| < 115 DDD | 259/1314 | 0.91 (0.78–1.06) | 0.83 (0.71–0.97)∗ |
| ≥ 115 DDD | 118/513 | 0.93 (0.76–1.14) | 0.87 (0.71–1.07) |
aCrude HR, relative hazard ratio; bAdjusted HR, multivariable analysis including age, sex, hormone therapy, treatment and comorbidities of coronary artery disease (CAD), diabetes, hypertension, stroke, and chronic obstructive pulmonary disease (COPD); cThe cumulative defined daily dose (DDD) is partitioned in to 2 segments by median; ∗P < 0.05; ∗∗∗P < 0.001.